Neal Murphy, MD, is a hematologist/oncologist who is dedicated to providing the best, personalized care to patients using the most advanced and up-to-date treatments available. Dr. Murphy received his Bachelor of Arts from Cornell University and his Doctor of Medicine from the Lewis Katz School of Medicine at Temple University. He went on to complete his internal medicine residency at the Donald and Barbara Zucker School of Medicine at Hofstra. At Hofstra, he completed the residency research track, where he received 1st place for translational research in the 2018 Lawrence Scherr Scholarly Activity Awards Competition and was also inducted into the Alpha Omega Alpha Honor Society. Dr. Murphy subsequently worked for one year as an academic hospitalist at Long Island Jewish Medical Center, followed by completing his hematology/oncology fellowship at the Donald and Barbara Zucker School of Medicine. He remains an Assistant Professor at the Donald and Barbara Zucker School of Medicine. Dr. Murphy has dedicated his time to research focusing on kidney and bladder cancer. Dr. Murphy completed two translational research studies, including "Prognostic molecular signatures for metastatic potential in clinically low-risk stage I and II clear cell renal cell carcinomas,” which was published in the prestigious journal Frontiers in Oncology, and "Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle-invasive bladder cancer” which was published in another reputable journal, Oncotarget. Dr. Murphy has several other peer-reviewed publications and has presented his work at national conferences. He remains passionate about optimizing treatments in hematology/oncology, and treats a broad spectrum of diseases with a focus on genitourinary, lung, head and neck, colorectal and skin malignancies, as well as multiple myeloma and lymphoma.